PharmTech AI Pulse Check panelists explain why attribution, audit trails, and sign-off matter more than AI watermark detection for GxP quality teams.
News|Articles|June 13, 2019
- Pharmaceutical Technology\'s In the Lab eNewsletter-07-02-2019
- Volume 14
- Issue 7
Aptar Acquires Nanopharm and Gateway Analytical
Author(s)Pharmaceutical Technology Editors
The acquisitions, totaling $50 million, are expected expand Aptar Pharma’s service offerings to support complex product development.
Advertisement
On June 10, 2019, AptarGroup announced that it has acquired two pharmaceutical services companies, Nanopharm and Gateway Analytical, for a combined price of approximately $50 million.
Nanopharm, located in Newport, UK, is a provider of orally inhaled and nasal drug product design and development services. Gateway Analytical, located in Gibsonia, PA, provides particulate detection and predictive analytical services to customers developing injectable medicines.
Both acquisitions bring complementary analytical, testing, and development services for all stages of drug development and commercialization. The acquisitions are part of Aptar’s strategy to broaden its service portfolio to support complex product development. Aptar states that the expanded services platform will enable its pharma arm to collaborate earlier with customers to support their complex drug formulations and delivery requirements.
“We are delighted to welcome the talented teams of Nanopharm and Gateway and their customers to Aptar Pharma,” commented Gael Touya, president of Aptar Pharma, in a company press release. “Their expertise and capabilities will deepen our current range of services offered to customers who are developing and testing inhaled and injected medicines. This enables us to participate in a broader spectrum of the pre-clinical, clinical trial, and market-launch phases of drug development.”
Source:
Articles in this issue
over 7 years ago
Translating Rich Data to Useful Informationover 7 years ago
The Need to Harmonize Good Laboratory Practicesover 7 years ago
HCP Kit for Automated Impurity Analysis of Biotherapeuticsover 7 years ago
Advanced Five-Laser Flow Cytometerover 7 years ago
SCIEX Systems Advance Lab Analyticsover 7 years ago
Agilent’s New Flow Cytometer Enhances Cell Analysisover 7 years ago
Optofluidic Platform to Aide in Immunotherapy Developmentover 7 years ago
International Survey Uncovers Challenges in Laboratory Workflowsover 7 years ago
Sanofi, Google to Develop New Healthcare Innovation LabAdvertisement
Related to this article
Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
The FDA approves oral pritelivir for drug-resistant herpes sores in immunocompromised patients; what it means for antiviral development and manufacturing.
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Richard Jaenisch examines whether FDA's NAM pathway truly shortens drug pipelines or just shifts the evidentiary burden elsewhere.
Susan J. Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied with regarding standards set by international pharmacopoeias.
Advertisement
Advertisement